Improvement of assessment in surrogate endpoint and safety outcome of single-arm trials for anticancer drugs

Abstract

Single-arm trials (SATs) and surrogate endpoints were adopted as pivotal evidence for accelerated approval of anticancer drugs for more than 30 years. However, concerns regarding clinical evidence ...